Evidence map›Paper›PMID 29971602›Full record

Trial reportInternational journal of hematology2018

Clinical characteristics of pediatric patients with myeloid sarcoma without bone marrow involvement in Japan.

Takashi Taga, Toshihiko Imamura, Kentaro Nakashima, Naoko Maeda, Akihiro Watanabe, Yuji Miyajima, Sachi Sakaguchi, Hitoshi Sano, Daiichiro Hasegawa, Hirohide Kawasaki and 6 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 15 institutions in 1 country.

Takashi TagaLeukemia/Lymphoma Committee of Japanese Society of Pediatric Hematology and Oncology, Tokyo, Japan. ttaga@belle.shiga-med.ac.jp.
Toshihiko ImamuraLeukemia/Lymphoma Committee of Japanese Society of Pediatric Hematology and Oncology, Tokyo, Japan.
Kentaro NakashimaDepartment of Pediatrics, Graduate School of Medicine, Kyushu University, Fukuoka, Japan.
Naoko MaedaDepartment of Pediatrics, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan.
Akihiro WatanabeDepartment of Pediatrics, Niigata Cancer Center Hospital, Niigata, Japan.
Yuji MiyajimaDepartment of Pediatrics, Anjo Kosei Hospital, Anjo, Japan.
Sachi SakaguchiDepartment of Pediatrics, Juntendo University Hospital, Tokyo, Japan.
Hitoshi SanoDepartment of Pediatrics, Tottori University Hospital, Yonago, Japan.
Daiichiro HasegawaDepartment of Hematology/Oncology, Hyogo Children's Medical Center, Kobe, Japan.
Hirohide KawasakiLeukemia/Lymphoma Committee of Japanese Society of Pediatric Hematology and Oncology, Tokyo, Japan.
Souichi AdachiLeukemia/Lymphoma Committee of Japanese Society of Pediatric Hematology and Oncology, Tokyo, Japan.
Masatoshi TakagiLeukemia/Lymphoma Committee of Japanese Society of Pediatric Hematology and Oncology, Tokyo, Japan.
Katsuyoshi KohLeukemia/Lymphoma Committee of Japanese Society of Pediatric Hematology and Oncology, Tokyo, Japan.
Atsushi ManabeLeukemia/Lymphoma Committee of Japanese Society of Pediatric Hematology and Oncology, Tokyo, Japan.
Tomohiko TakiLeukemia/Lymphoma Committee of Japanese Society of Pediatric Hematology and Oncology, Tokyo, Japan.
Yasushi IshidaLeukemia/Lymphoma Committee of Japanese Society of Pediatric Hematology and Oncology, Tokyo, Japan.
Anjo Kosei Hospital · JPEhime Prefectural Central Hospital · JPJuntendo University Hospital · JPKansai Medical University · JPKobe Children's Hospital · JPKyorin University · JPKyoto Prefectural University of Medicine · JPKyoto University · JPKyushu University · JPNagoya Medical Center · JPNiigata Cancer Center Hospital · JPSaitama Children's Medical Center · JPSt. Luke's International Hospital · JPTokyo Medical and Dental University · JPTottori University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid sarcoma (MS) is a rare neoplastic condition that is often described in association with acute myeloid leukemia (AML). MS in childhood has received little attention, particularly in Japan. We carried out a nationwide retrospective analysis of Japanese children diagnosed with MS without bone marrow involvement. Inclusion criteria were diagnosis of MS at younger than 20 years of age between January 1, 2000 and December 31, 2013. There was a predominance of males (8:2), and the median age at MS diagnosis was 4 years. Sites of involvement varied and included skin (n = 3), head and/or neck (n = 2), and multiple sites (n = 2). Karyotypes were evaluated in seven patients, with one individual carrying t(8;21) and t(9;11). Four patients developed bone marrow involvement 2-55 months after diagnosis of MS. All patients received chemotherapy for de novo AML and two individuals received HSCT in first remission. Seven of ten patients survived for 50-152 months (median, 93 months) without disease after initial chemotherapy. This retrospective study confirmed that pediatric MS without bone marrow involvement in Japan is a very rare disease. MS patients responded favorably to therapies for de novo AML, and HSCT in first remission was not indicated for all patients.

Indexed as

Sarcoma, MyeloidAbnormal KaryotypeAdolescentBone MarrowChildChild, PreschoolDisease-Free SurvivalFemaleHumansInfantJapanMaleSurvival RateAMLChemotherapyChildrenMyeloid sarcoma

Identifiers

PMID29971602
OpenAlexW2810087153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.